With the goal of identifying patients with Duchenne muscular dystrophy (DMD) in the Middle East and North Africa, genetic diagnostics company Centogene has announced a year-long strategic collaboration with Sarepta Therapeutics. The agreement calls for patients who are multiplex litigation-dependent probe amplification (MLPA) negative to undergo diagnostic Centogene testing using deletion/duplication analysis and full-length sequencing of the DMD gene. In addition, the company will provide diagnostic testing to physicians treating patients with DMD-related symptoms. MLPA is a very sensitive and fast technique used to identify deletions and duplications, and can evaluate all 79 exons in dystrophin genes in DMD patients. Centogene is a global leader in using genetic and proteomic knowledge to enable patients, clinicians and pharmaceutical partners to identify, and accelerate treatments for, rare diseases.

Source: The North Africa Journal March 04, 2019 12:56 UTC